Standout Papers
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy (2019)
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma (2020)
Immediate Impact
28 by Nobel laureates 9 from Science/Nature 68 standout
Citing Papers
Naturally occurring T cell mutations enhance engineered T cell therapies
2024 StandoutNature
Antibody–drug conjugates come of age in oncology
2023 Standout
Works of Elaina M. Gartner being referenced
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019 Standout
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Elaina M. Gartner | 652 | 945 | 417 | 40 | 1.7k | |
| Maria Matsangou | 633 | 752 | 612 | 39 | 1.7k | |
| Matthew T. Hueman | 462 | 781 | 498 | 53 | 1.7k | |
| Tooru Shiratori | 764 | 514 | 426 | 36 | 1.7k | |
| Qiu-Yan Chen | 404 | 922 | 382 | 50 | 1.7k | |
| P. M. Schlag | 346 | 653 | 348 | 68 | 1.4k | |
| Walter Seelentag | 482 | 822 | 682 | 44 | 2.1k | |
| Saeed Rafii | 391 | 999 | 508 | 33 | 1.4k | |
| J Richard | 519 | 1174 | 465 | 38 | 2.0k | |
| Gloria A. Niehans | 689 | 710 | 827 | 45 | 2.1k | |
| Hao-Yuan Mo | 341 | 655 | 383 | 34 | 1.3k |
All Works
Loading papers...